Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Operating Expenses (2016 - 2025)

Avalo Therapeutics' Operating Expenses history spans 12 years, with the latest figure at $19.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 46.64% year-over-year to $19.8 million; the TTM value through Dec 2025 reached $73.0 million, up 5.84%, while the annual FY2025 figure was $73.0 million, 5.85% up from the prior year.
  • Operating Expenses reached $19.8 million in Q4 2025 per AVTX's latest filing, up from $19.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $32.8 million in Q1 2024 to a low of $4.0 million in Q3 2023.
  • Average Operating Expenses over 5 years is $15.7 million, with a median of $14.1 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: crashed 63.28% in 2023, then soared 253.59% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $18.2 million in 2021, then crashed by 46.37% to $9.8 million in 2022, then fell by 15.61% to $8.2 million in 2023, then skyrocketed by 64.09% to $13.5 million in 2024, then soared by 46.64% to $19.8 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Operating Expenses are $19.8 million (Q4 2025), $19.2 million (Q3 2025), and $19.3 million (Q2 2025).